Docket No.:

TOYA108.013APC

May 25, 2006 Page 1 of 1

MAY 3 0 2006

Please Direct All Correspondence to Customer Number 20995

TRANSMITTAL LETTER INFORMATION DISCLOSURE STATEMENT

rpplicant

Higuchi, et al.

App. No

10/572,404

Filed

March 16, 2006

For

DRUG AND FOOD OR DRINK FOR

IMPROVING HYPERGLYCEMIA

Examiner

Unknown

Art Unit

Unknown

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

May 25, 2006

(Date)

Che Swyden Chereskin, Ph.D., Reg. No. 41,466

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing 1 reference for consideration. One reference is enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404

INFORMATION DISCLOSURE STATEMENT

Applicant

Higuchi, et al.

App. No

10/572,404

Filed

March 16, 2006

For

DRUG AND FOOD OR DRINK FOR

IMPROVING HYPERGLYCEMIA

Examiner

Unknown

Art Unit

Unknown

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing and enclosing 1 reference to be considered by the Examiner.

This reference is being resubmitted to correct a clerical error when the reference was originally submitted on May 18, 2006. The page numbers of the reference are now correctly shown on the SB/08 Equivalent as 245-248.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: May 25, 2006

By:

y: _____(___

Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404

			Application No.	10/572,404	
	INFOR	MATION DISCLOSURE	Filing Date	March 16, 2006	
	CTATI	TMENT DV ADDLICANT	First Named Inventor	Higuchi, et al.	
STATEMENT BY APPLICANT			Art Unit	Unknown	
6,	Mariti	ple sheets used when necessary)	Examiner	Unknown	
	2006	SHEET 1 OF 1	Attorney Docket No.	TOYA108.013APC	
	- 0 to - >	(

WAY 3"	- <u>F</u>	U.S. PATENT DOCUMENTS				
Initials	cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	τ¹

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/o country where published.			
		Bunyapraphatsara, et al. "Antidiabetic Activity of <i>Aloe vera</i> L. Juice II. Clinical Trial in Diabetes Mellitus Patients in Combination with Glibenclamide," <i>Phytomedicine</i> , Vol. 3, No. 3, pp. 245-248, 1996.		

2611319 051806

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.